OBJECTIVES: In 2010, there were estimated to be in excess of 75,000 Herceptin IV infusions in England, putting ever-increasing demands on hospital resource. This analysis aims to estimate the change in resource use and subsequent time and cost savings that could result from using Herceptin SC in three different English settings; (1) hospital, (2) community and (3) patient self-administration at home versus Herceptin IV in the hospital. METHODS: Routine data on Herceptin IV-related hospital use and processes was collected using the Chemotherapy Capacity Planning Tool. Interviews were conducted with a number of English centres in order to determine likely changes to key delivery inputs as a result of using Herceptin SC. An economic model was developed to estimate average time and cost savings from delivering Herceptin SC in the three settings assuming 200 patients are given a full treatment course of Herceptin and the capacity of a hospital is 10 IV chairs running 2 full days Herceptin clinics per week. Unit costs were taken from the Personal Social Service Research Unit. RESULTS: A 100% switch of 200 Herceptin patients to SC leads to a fall in total expenditure of 271,000, 1,200,000 and 1,500,000 in settings (1), (2), and (3) respectively. This is largely due to reductions in resource costs from 2,937 hours of IV chair time saved in all settings, 2,691 nurse hours saved in (1) and (2) and 5,712 in (3), and 2,102 pharmacist technician hours saved in (1) and (2) and 4,532 in (3). CONCLUSIONS: A switch from hospital-based IV to SC Herceptin leads to substantial time and cost savings whether delivered in the hospital, in the community or via patient self-administration. Therefore if Herceptin patients received SC administration instead of IV, this could potentially increase hospitals' throughput and overall efficiency. Any savings could be reinvested elsewhere in order to improve overall patient care.
Samanta, K., Moore, L., Jones, G., Evason, J., & Owen, G. (2012). PCN39 Potential Time and Cost Savings with Herceptin (Trastuzumab) Subcutaneous (SC) Injection Versus Herceptin Intravenous (IV) Infusion: Results from Three Different English Patient Settings. Value in Health, 15(7), A415. https://doi.org/10.1016/j.jval.2012.08.1232